Literature DB >> 31255259

Rate of BRCA mutation in patients tested under NCCN genetic testing criteria.

Anna C Beck1, Haimiao Yuan1, Junlin Liao1, Pamela Imperiale2, Krysten Shipley1, Lillian M Erdahl1, Sonia L Sugg1, Ronald J Weigel1, Ingrid M Lizarraga3.   

Abstract

BACKGROUND: BRCA genetic testing is recommended by the National Comprehensive Cancer Network (NCCN) in breast cancer patients who meet specific criteria. Limited data are available on the likelihood of detecting a mutation when these guidelines are followed.
METHODS: A retrospective chart review examined patients with breast cancer who underwent BRCA testing based on NCCN guidelines.
RESULTS: Twelve (6.0%) of the 199 patients had a deleterious BRCA mutation. Family history of BRCA mutations (50%, p = 0.019), age ≤45 at diagnosis (9.7%, p = 0.034) and meeting ≥3 NCCN criteria (13.3%, p = 0.03) yielded the highest rates of BRCA mutation. Having a family history of BRCA mutation and age ≤45 were associated with increased rate of BRCA mutation on multivariate analysis (OR 14.3, CI 1.2-166.3; OR 11.6, CI 1.2-108.6).
CONCLUSION: Select NCCN criteria are associated with higher rates of BRCA mutations. Waiting for genetic testing results to guide surgical management may be warranted in this subset of patients.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRCA; Breast cancer; Family history; Genetic testing; NCCN

Mesh:

Year:  2019        PMID: 31255259      PMCID: PMC7266680          DOI: 10.1016/j.amjsurg.2019.06.012

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  33 in total

1.  Genetic Testing for Hereditary Breast Cancer: The Decision to Decline.

Authors:  V Brook White; Kendall K Walsh; Kimberly Showers Foss; Lisa Amacker-North; Stacy Lenarcic; Lindsay McNeely; Richard L White
Journal:  Am Surg       Date:  2018-01-01       Impact factor: 0.688

2.  Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.

Authors:  Caiqian Cropper; Ashley Woodson; Banu Arun; Carlos Barcenas; Jennifer Litton; Sarah Noblin; Diane Liu; Minjeong Park; Molly Daniels
Journal:  J Natl Compr Canc Netw       Date:  2017-06       Impact factor: 11.908

3.  BRCA2 germline mutations in male breast cancer cases and breast cancer families.

Authors:  F J Couch; L M Farid; M L DeShano; S V Tavtigian; K Calzone; L Campeau; Y Peng; B Bogden; Q Chen; S Neuhausen; D Shattuck-Eidens; A K Godwin; M Daly; D M Radford; S Sedlacek; J Rommens; J Simard; J Garber; S Merajver; B L Weber
Journal:  Nat Genet       Date:  1996-05       Impact factor: 38.330

4.  Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.

Authors:  E Warner; W Foulkes; P Goodwin; W Meschino; J Blondal; C Paterson; H Ozcelik; P Goss; D Allingham-Hawkins; N Hamel; L Di Prospero; V Contiga; C Serruya; M Klein; R Moslehi; J Honeyford; A Liede; G Glendon; J S Brunet; S Narod
Journal:  J Natl Cancer Inst       Date:  1999-07-21       Impact factor: 13.506

5.  Time to Surgery and Breast Cancer Survival in the United States.

Authors:  Richard J Bleicher; Karen Ruth; Elin R Sigurdson; J Robert Beck; Eric Ross; Yu-Ning Wong; Sameer A Patel; Marcia Boraas; Eric I Chang; Neal S Topham; Brian L Egleston
Journal:  JAMA Oncol       Date:  2016-03       Impact factor: 31.777

6.  Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.

Authors:  Nadine Tung; Nancy U Lin; John Kidd; Brian A Allen; Nanda Singh; Richard J Wenstrup; Anne-Renee Hartman; Eric P Winer; Judy E Garber
Journal:  J Clin Oncol       Date:  2016-03-14       Impact factor: 44.544

7.  Negative Genetic Testing Does Not Deter Contralateral Prophylactic Mastectomy in Younger Patients with Greater Family Histories of Breast Cancer.

Authors:  Frederick Wang; Dominic Amara; Anne Warren Peled; Hani Sbitany; Robert D Foster; Cheryl A Ewing; Michael Alvarado; Laura J Esserman
Journal:  Ann Surg Oncol       Date:  2015-07-28       Impact factor: 5.344

Review 8.  BRCA1 and BRCA2: 1994 and beyond.

Authors:  Steven A Narod; William D Foulkes
Journal:  Nat Rev Cancer       Date:  2004-09       Impact factor: 60.716

9.  Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer.

Authors:  Seth Rummel; Erika Varner; Craig D Shriver; Rachel E Ellsworth
Journal:  Breast Cancer Res Treat       Date:  2012-11-29       Impact factor: 4.872

10.  Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations.

Authors:  A Moran; C O'Hara; S Khan; L Shack; E Woodward; E R Maher; F Lalloo; D G R Evans
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

View more
  4 in total

1.  Double Heterozygous Mutations in the BRCA2 and ATM Genes: A Case Report and Review of the Literature.

Authors:  Neslihan Duzkale Teker; Nilnur Eyerci
Journal:  Breast Care (Basel)       Date:  2020-10-29       Impact factor: 2.268

2.  The Relationship of Mutation Carriage of BRCA1/2 and Family History in Triple-Negative Breast Cancer: Experience from a Diagnostic Center in Turkey.

Authors:  Neslihan Duzkale; Olcay Kandemir
Journal:  Eur J Breast Health       Date:  2021-03-31

3.  Early-onset breast cancer in a woman with a germline mobile element insertion resulting in BRCA2 disruption: a case report.

Authors:  Natalie Deuitch; Shao-Tzu Li; Eliza Courtney; Tarryn Shaw; Rebecca Dent; Veronique Tan; Lauren Yackowski; Rebecca Torene; Windy Berkofsky-Fessler; Joanne Ngeow
Journal:  Hum Genome Var       Date:  2020-08-25

Review 4.  Executive Summary of the Early-Onset Breast Cancer Evidence Review Conference.

Authors:  David Chelmow; Mark D Pearlman; Amy Young; Laura Bozzuto; Sandra Dayaratna; Myrlene Jeudy; Mallory E Kremer; Dana Marie Scott; Julia Sage O'Hara
Journal:  Obstet Gynecol       Date:  2020-06       Impact factor: 7.623

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.